Novel proteomic technologies to address gaps in pre-clinical ovarian cancer biomarker discovery efforts.
Helen A JordanStefani N ThomasPublished in: Expert review of proteomics (2023)
biomarkers with regulatory approval will have significant benefits for patients. Multiplexed affinity-based assay platforms and novel mass spectrometry methods are capable of quantifying low abundance proteins to aid biomarker discovery efforts by enabling the robust analytical interrogation of the ovarian cancer proteome.
Keyphrases
- mass spectrometry
- high throughput
- end stage renal disease
- small molecule
- liquid chromatography
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- transcription factor
- single cell
- patient reported outcomes
- antibiotic resistance genes
- microbial community
- tandem mass spectrometry